Rigel Pharmaceuticals, Inc.
RIGL
$32.13
$2.769.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 8.65M | 268.07M | 27.90M | 59.61M | 11.45M |
| Total Depreciation and Amortization | 597.00K | 601.00K | 603.00K | 607.00K | 604.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.86M | -243.35M | 2.90M | -36.96M | 3.13M |
| Change in Net Operating Assets | -12.39M | -3.34M | -7.37M | 7.27M | -16.08M |
| Cash from Operations | 2.73M | 21.98M | 24.03M | 30.54M | -893.00K |
| Capital Expenditure | -- | 12.00K | -12.00K | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -7.98M | -25.37M | -33.16M | -23.28M | -10.55M |
| Cash from Investing | -7.98M | -25.36M | -33.18M | -23.28M | -10.55M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -7.50M | -7.50M | -- | -- | -- |
| Issuance of Common Stock | 321.00K | 2.93M | 4.27M | 418.00K | 484.00K |
| Repurchase of Common Stock | -3.74M | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -10.92M | -4.57M | 4.27M | 418.00K | 484.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.17M | -7.95M | -4.87M | 7.68M | -10.96M |